Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This is a single centre, double-blind, randomised, parallel group, repeated dose asthmatic
subjects. Subjects will receive AER 001 (60 mgs) or placebo twice daily for 28 days. Before
and after treatment subjects will be experimentally challenged with inhaled allergen to
induce decreases in lung function. The primary outcome is late phase response to allergen as
measured by the average percent change in FEV1 from 4-10 hours following allergen. Because
AER 001 is a Th2 anti-inflammatory, it is hypothesized that AER 001 treatment will inhibit
the late phase response to allergen challenge.